BeiGene
2025.09.26
09:24
Hong Kong stocks related to innovative drug concepts opened lower collectively, with BeiGene (06160.HK) opening 3.5% lower, Tigermed (03347.HK) and Kangfang Biopharma (09926.HK) opening more than 2% lower, and Fosun Pharma (02196.HK) opening 1.91% lower.
09:22
Hong Kong stocks opened: Hang Seng Index opened 0.8% lower, CXO and innovative drug concept stocks opened lower
Hong Kong stocks opened lower, with the Hang Seng Index opening 0.8% lower and the Hang Seng Tech Index 0.97% lower. CXO and innovative drug stocks all opened lower, with BeiGene down 3.5%, WuXi AppTec down 2.07%, and Fosun Pharma down 1.91%, following Trump's announcement that he would impose a 100% tariff on patented and branded drugs.
2025.09.24
16:04
Chinese stocks in the US stock market rose before the opening
Chinese stocks listed in the U.S. generally rose before the market opened, with Alibaba up 9%, Baidu up 5%, JD.com up 3%, Bilibili and NIO up 2%, Pinduoduo and Ctrip up 1%, and BeiGene up 0.5%.
2025.09.19
15:09
Unusual movements in call auctions of several large-cap stocks
Several stocks saw significant moves in the closing call auction. Eosun, InnoLight, WuXi AppTec, and BeiGene all rallied, while China National Nuclear Power, China Unicom, and Wanhua Chemical all declined. On a related note, FTSE Russell announced on September 3rd quarterly review changes to the FTSE China 50 and other indices, effective after the market close on September 19th. The FTSE China A50 Index now includes BeiGene-U, Eosun, WuXi AppTec, and InnoLight, while excluding China National Nuclear Power, China Unicom, NARI, and Wanhua Chemical.
2025.09.12
16:56
BeiGene: Employees purchased 62,962 American Depositary Shares
BeiGene announced that as of August 29, 2025, the last day of the subscription period, 3,932 participants purchased 62,962 American Depositary Shares (ADSs) under its 2018 Employee Stock Purchase Plan. This represents a total of 818,500 ADSs, representing approximately 0.05% of the company's outstanding shares. The price per ADS was US$208.70, or approximately HK$125.06 per ordinary share. Authorized payroll deductions during the subscription period amounted to US$13.4495 million.
11:27
Several pharmaceutical companies are concerned about market rumors that the US may impose restrictions on innovative drugs from China, but believe that these rumors will not currently affect the prospects for Chinese innovative drugs to go global.
After yesterday's sharp drop, Hong Kong's innovative drug stocks rebounded across the board today. As of press time, Alphamab Oncology B shares rose over 14%, Hutchison MediPharma rose over 6%, Zai Lab and Lepu Biopharmaceuticals B shares rose over 5%, and CASI Biopharmaceuticals B shares rose over 4%. Several pharmaceutical companies responded to market rumors that the US may impose restrictions on innovative drugs from China, but they believe these rumors do not currently affect the overseas expansion of Chinese innovative drugs. Market analysts believe that leading biotech companies, represented by BeiGene and Innovent Biologics, are expected to achieve a profitability inflection point in 2025 and maintain high growth thereafter. With the improvement of industrialization capabilities and the expansion of product lines, more biotech companies are expected to enter a profit cycle in the future.
2025.09.11
16:02
Most Chinese stocks in the US stock market rose before the market opened, with BeiGene rising 3%.
Most Chinese stocks listed in the U.S. rose before the market opened, with BeiGene up 3%, NIO and Alibaba up 2%, Xpeng Motors and Ctrip up 1%, Pinduoduo up 0.6%, JD.com up 0.2%, and Li Auto down 0.8%.
11:23
The Hong Kong stock market saw a collective drop in innovative drug stocks, with unfavorable news coming from the market.
Innovative drug stocks plummeted in early trading on the Hong Kong stock market, with declines exceeding 6% in the oncology, assisted reproductive, innovative drug, and CXO sectors. A-share innovative drug stocks also followed suit, with BeiGene and Innovent Biologics falling over 10%, and Sinopharm, Huahai Pharmaceutical, Chipscreen Biopharma, Rongchang Biopharma, and WuXi AppTec dropping over 6%. Despite negative market news, research institutions strongly advocated for the sell-off, viewing it as a buying opportunity. They also believed that the upward trend in the A-share and Hong Kong pharmaceutical sectors is far from over, and that the main upward trend is expected to continue in the medium to long term. News reports circulated across investment circles that the Trump administration is considering strict restrictions on pharmaceuticals imported from China, including a draft executive order that could disrupt experimental therapies invented in China, potentially impacting the US pharmaceutical industry and limiting the availability of generic drugs and advanced therapies. However, the White House stated that it was not "actively considering" the draft order.
10:30
Innovative drug stocks plummeted as reports emerged that the Trump administration was preparing an executive order targeting Chinese pharmaceuticals.
Innovative drug stocks plummeted in early trading today (September 11th), with CXO-related, weight loss, and innovative drug concepts all falling by over 1%. Even leading innovative drug companies with a market value exceeding 100 billion yuan were not immune to the correction, with BeiGene-U and Hengrui Medicine both falling by over 5%. On the news front, it was reported that the Trump administration is considering an executive order targeting Chinese pharmaceuticals.
09:28
Innovative drug concept stocks opened sharply lower, with BeiGene falling over 10%.
Innovative drug concept stocks opened sharply lower, with BeiGene falling more than 10%, WuXi AppTec and Tiger Pharmaceuticals falling more than 7%, and Hengrui Medicine, Junshi Biosciences, and CStone Pharmaceuticals falling more than 5%.
09:23
Most Hong Kong-listed pharmaceutical stocks opened lower, with Hansoh Pharmaceutical (03692.HK) opening down 14.98%, Fuhong Hanlin (02696.HK) opening down 11.84%, and many stocks including CSPC Pharmaceutical Group (01093.HK), WuXi Biologics (02269.HK), and BeiGene (06160.HK) opening lower.
09:21
Hong Kong stocks opened: Hang Seng Index opened 0.81% lower, with most new drug concept stocks opening lower
At the Hong Kong stock market opening, the Hang Seng Index opened 0.81% lower, and the Hang Seng Tech Index opened 0.97% lower. Most innovative drug stocks opened lower, with WuXi Biologics down 9.52%, BeiGene down 9.32%, and WuXi AppTec down 6.95%.
2025.09.10
19:36
BeiGene (BGNE.O)'s U.S. stock price fell by more than 12% in pre-market trading, but the decline has now narrowed to 9%.
19:33
BeiGene's US stock price fell more than 12% before the market opened
BeiGene's U.S. stock price fell more than 12% in pre-market trading and is now trading at $308.22.
2025.09.09
09:51
A-share innovative drug concept stocks rose in early trading, with Rongchang Biopharma rising more than 14%, Yipinhong and Jincheng Pharmaceutical rising more than 7%, Junshi Biosciences and BeiGene rising more than 6%, and Baili Tianheng and Kangchen Pharmaceutical following suit.
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
China Great Wall: The company's AI server power supply has officially started production

2025-10-27

Most Chinese stocks in the US stock market rose before the market opened, with Baidu rising 4%.

2025-10-27

Meituan's video generation model is officially released and open sourced

2025-10-27

Gree and JD.com's sales volume is expected to exceed 20 billion yuan this year

2025-10-27

In the first three quarters, the core output value of Guangxi's industrial artificial intelligence increased by more than 60% year-on-year

2025-10-25

ASIA TECH WIRE

Grasp technology trends

Download